Your session is about to expire
← Back to Search
Perampanel for Epilepsy
Study Summary
This trial will help determine how well the drug perampanel works in treating patients with epilepsy by measuring how much of the drug crosses the blood brain barrier.
- Epilepsy
- Seizures
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 4 trial • 54 Patients • NCT03288129Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
How many individuals have registered for this experiment thus far?
"Affirmative. The current records on clinicaltrials.gov indicate that this trial, first posted November 1st 2019, is currently recruiting participants. 25 subjects are required from one medical site."
Are there available slots left for participation in this clinical experiment?
"Per the information found on clinicaltrials.gov, this experiment is actively seeking participants as of today's date. The trial was initially published to the site on November 1st 2019 and has since been updated lastly on September 8th 2021."
Has the FDA sanctioned Perampanel for therapeutic applications?
"After assessing the safety of Perampanel, our team at Power awarded it a score of 3 due to its Phase 4 status hinting that this drug is approved."
What prior investigations have been conducted utilizing Perampanel?
"Currently, 11 studies concerning Perampanel are underway with none of them situated in Phase 3. Most research activities for this medication take place in New york City but there are 93 other locations conducting investigations as well."
Is this a groundbreaking research initiative?
"Presently, there are 11 active trials for Perampanel spanning 51 cities and 9 countries. Starting in 2017 with an Eisai Inc.-sponsored trial involving 60 patients, over the past four years a total of 52 studies have concluded their drug approval stage."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger